A Pilot, Phase II Study With a Prospective, Randomized, Cross-Over, Placebo-Controlled, Double-Blind Design to Assess the Short-Term Effects of Tolvaptan Plus Placebo vs Tolvaptan Plus Octreotide LAR Combination Therapy in ADPKD Patients With Normal Kidney Function or Hyperfiltration
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Sep 2018
At a glance
- Drugs Octreotide (Primary) ; Tolvaptan (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Therapeutic Use
- Acronyms TOOL
- 30 Aug 2018 Planned End Date changed from 1 Jul 2020 to 1 Sep 2020.
- 30 Aug 2018 Planned primary completion date changed from 1 Jul 2020 to 1 Sep 2020.
- 30 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Sep 2018.